Company

NanoMosaic LLC

NanoMosaic develops nanoneedle technology for proteomics, biomarker analysis, and disease detection.

About

NanoMosaic LLC develops MosaicNeedle, a nanoneedle platform for proteomics and multi-omics applications, and Tessie, a platform for early disease detection and prognosis. Its technology supports sensitive, label-free analysis of proteins and nucleic acids. Founded in 2018 and based in Massachusetts, US, the company raised USD 40.75 million in Series A funding in December 2021, led by RA Capital, with Insight Partners, Pura Vida Investments, Time BioVentures, and TigerGene LLC participating.

1Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in